ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Limited has issued the notice for its 31st Annual General Meeting scheduled for September 12, 2026. Shareholders will consider key resolutions and director appointments.
Shree Ganesh Remedies Limited has filed its Annual Report for FY 2025-26. It also includes the notice for the 31st Annual General Meeting on September 12, 2026.
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies announced its Q1FY27 financial results. Revenue from operations stood at ₹14.36 Crore, with a PAT of ₹1.12 Crore.
Shree Ganesh Remedies Limited has appointed M/s. M. I. Prajapati & Associates LLP as the company's Cost Auditor for a term of 12 months.
Shree Ganesh Remedies Ltd reported revenue from operations of ₹14.4 Cr (-41.7% YoY) and net profit of ₹1.1 Cr (-67.6% YoY) for Q1 FY27.
Shree Ganesh Remedies Ltd has scheduled a Board Meeting for August 12, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Shree Ganesh Remedies Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with regulatory requirements.
Shree Ganesh Remedies appointed Ms. Hiral Ankitkumar Shah as Additional Non-Executive Independent Director. The appointment is effective July 17, 2026, for a five-year term.
Shree Ganesh Remedies clarified that recent share price movements are market-driven. The company confirms all necessary disclosures have been made to exchanges.
Shree Ganesh Remedies filed its Annual Secretarial Compliance Report for FY2026. The auditor noted a prior ₹0.00 Crore fine for delayed results submission in 2024.
Shree Ganesh Remedies reported Q4 FY26 revenue of INR 33.20 cr (up 36% YoY). Management characterized FY26 as a consolidation year, focusing on CRAMS pilot trials and capacity expansion.
Management characterized FY26 as a consolidation year, focusing on groundwork for CRAMS. While Q4 showed strong sequential recovery, full-year growth remained flat as the company pivoted from generic domestic markets to specialized global molecules.
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.
Shree Ganesh Remedies Ltd reported revenue from operations of ₹33.2 Cr (+36.1% YoY) and net profit of ₹6.3 Cr (-4.5% YoY) for Q4 FY26.
Shree Ganesh Remedies reported its FY 2025-26 audited financial results alongside auditor reports. The board also re-appointed M/s. S N D K & Associates as internal auditors.
Shree Ganesh Remedies Ltd scheduled a board meeting on May 14, 2026, to approve FY2026 audited financial results. The trading window remains closed until May 16, 2026.
Shree Ganesh Remedies Ltd reported net profit of ₹3.1 Cr (-42.6% YoY) for Q3 FY26.
Shree Ganesh Remedies Ltd announced the results of its Extra Ordinary General Meeting held on April 06, 2026. Shareholders approved the re-appointment of Mr. Parth Chandulal Kothia as Whole-time Director and CFO, and sanctioned a related party transaction for remuneration to Mr. Gunjan Chandulal Kothia. Both resolutions were passed with the requisite majority.
Shree Ganesh Remedies Ltd conducted an EGM on April 06, 2026. Shareholders approved the re-appointment of Mr. Parth Chandulal Kothia as Whole-time Director and CFO. Additionally, an ordinary resolution was passed regarding a related party transaction for remuneration payment to Mr. Gunjan Chandulal Kothia.